search
Back to results

Stem Cell Study for Patients With Leg Ulcer/Gangrene

Primary Purpose

Leg Pain, Ulcer, Gangrene

Status
Completed
Phase
Phase 1
Locations
Japan
Study Type
Interventional
Intervention
Autologous peripheral blood CD34 positive cell therapy
Sponsored by
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Leg Pain focused on measuring Ulcer/ gangrene, Leg diseases, Pain, Vascular diseases, Chronic limb ischemia, Peripheral artery disease

Eligibility Criteria

20 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Chronic severe CLI patients fulfilling all the following criteria are considered suitable for inclusion in the study. At least 6 months since the onset of CLI (Chronic peripheral artery disease or Buerger disease) Patients with luminal stenosis > 50% by leg angiography Age is between 20 and 80. Patients whose Rutherford's class is II-4, III-5, or III-6(Patients with rest pain or ischemic ulcer/necrosis) Patients for whom angioplasty and bypass surgery are not indicated because of anatomical or procedural reasons or frequent reocclusion/ restenosis following the traditional revascularization (No option patients) Patients who can give informed consent themselves in writing. Exclusion Criteria: Any one of the following exclusion criteria is sufficient to disqualify a patient from the study. Left ventricular ejection fraction < 25% Patients with a history of severe allergic reactions or side effects to G-CSF preparations or apheresis. Less than 6 months since last episode of myocardial/cerebral infarction. Patients with unstable angina, with a treatment rating of 3 in the Braunwald system, but a severity of III and a clinical rating of B or C. Patients with diabetic proliferating retinopathy (new Fukuda classification BI to BV). Patients with malignant tumor Patients with chronic rheumatoid arthritis. Patients with hematological disease (leukemia, myeloproliferative disease, or myelodysplastic syndromes). Patients currently suffering from or having a history of interstitial pneumonitis. Patients for whom cranial MRA reveals cerebral aneurysm. Patients for whom abdominal CT or ultrasonography reveals splenomegaly. Patients with cirrhosis of the liver. Patients who cannot discontinue Warfarin. Leukocytes less than 4,000/µL or exceeding 10,000/µL. Platelets less than 100,000/µL. Hemoglobin less than 10 g/dL. AST (GOT) exceeding 100 IU/L or ALT (GPT) exceeding 100 IU/L. Patients with severe neural disorder in their legs. Patients with gait disturbance for reasons other than CLI (such as sciatic neuralgia, or vasculitis), making exercise tolerance evaluation on a treadmill with stress ECG difficult. Pregnant or nursing patients, those who may be pregnant, or those who plan on becoming pregnant before the end of the study period. Any other reason that the Clinical Supervisors or Clinical Researchers may have for considering a case unsuitable for the study.

Sites / Locations

  • Kobe City General Hospital
  • Institute of Biomedical Research and Innovation

Outcomes

Primary Outcome Measures

Major amputation

Secondary Outcome Measures

Limb ischemia

Full Information

First Posted
September 13, 2005
Last Updated
February 6, 2009
Sponsor
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Collaborators
Institute of Biomedical Research and Innovation, Kobe, Hyogo, Japan, Kobe City General Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT00221143
Brief Title
Stem Cell Study for Patients With Leg Ulcer/Gangrene
Official Title
Phase I / II Clinical Trial Regarding Vascular Regeneration Therapy by Transplantation of Autologous Peripheral Blood Endothelial Progenitor Cells (CD34+ Cells) in No-Option Patients With Chronic Critical Limb Ischemia
Study Type
Interventional

2. Study Status

Record Verification Date
February 2009
Overall Recruitment Status
Completed
Study Start Date
November 2003 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
January 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Collaborators
Institute of Biomedical Research and Innovation, Kobe, Hyogo, Japan, Kobe City General Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to determine if stem cell therapy with one's own cells (autologous cells) delivered intramuscularly to one's leg with ulcer and/or gangrene due to poor blood flow will be safe and if it will relieve leg pain, increase blood flow, and/or cure the leg wound.
Detailed Description
Chronic critical limb ischemia (CLI) is a progressive disease, which arises as a result of atherosclerosis or vasculitis in leg arteries. Prognosis of chronic CLI is poor, and no effective treatments have been established in patients who are not eligible for the traditional revascularization therapies such as angioplasty and bypass procedures due to the inappropriate anatomy of the leg arteries or frequent reocclusion following revascularization. Therefore, it is necessary to establish novel revascularization treatment to improve prognosis of the no-option patients. We will study the safety and clinical efficiency of vascular regeneration by means of transplantation of autologous peripheral blood endothelial progenitor cells (CD34 positive cells) in patients with chronic CLI who are not eligible for traditional revascularization treatments. The primary endpoint is the primary efficacy score identified by toe brachial blood pressure index (TBPI), absolute claudication distance (ACD) and Wong Baker's pain rating scale, while the secondary endpoints are evaluation of safety, ankle brachial blood pressure index (ABPI), percutaneous tissue oxygen pressure (TcPO2), etc.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Leg Pain, Ulcer, Gangrene, Ischemia, Peripheral Vascular Diseases
Keywords
Ulcer/ gangrene, Leg diseases, Pain, Vascular diseases, Chronic limb ischemia, Peripheral artery disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
15 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Genetic
Intervention Name(s)
Autologous peripheral blood CD34 positive cell therapy
Primary Outcome Measure Information:
Title
Major amputation
Secondary Outcome Measure Information:
Title
Limb ischemia

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Chronic severe CLI patients fulfilling all the following criteria are considered suitable for inclusion in the study. At least 6 months since the onset of CLI (Chronic peripheral artery disease or Buerger disease) Patients with luminal stenosis > 50% by leg angiography Age is between 20 and 80. Patients whose Rutherford's class is II-4, III-5, or III-6(Patients with rest pain or ischemic ulcer/necrosis) Patients for whom angioplasty and bypass surgery are not indicated because of anatomical or procedural reasons or frequent reocclusion/ restenosis following the traditional revascularization (No option patients) Patients who can give informed consent themselves in writing. Exclusion Criteria: Any one of the following exclusion criteria is sufficient to disqualify a patient from the study. Left ventricular ejection fraction < 25% Patients with a history of severe allergic reactions or side effects to G-CSF preparations or apheresis. Less than 6 months since last episode of myocardial/cerebral infarction. Patients with unstable angina, with a treatment rating of 3 in the Braunwald system, but a severity of III and a clinical rating of B or C. Patients with diabetic proliferating retinopathy (new Fukuda classification BI to BV). Patients with malignant tumor Patients with chronic rheumatoid arthritis. Patients with hematological disease (leukemia, myeloproliferative disease, or myelodysplastic syndromes). Patients currently suffering from or having a history of interstitial pneumonitis. Patients for whom cranial MRA reveals cerebral aneurysm. Patients for whom abdominal CT or ultrasonography reveals splenomegaly. Patients with cirrhosis of the liver. Patients who cannot discontinue Warfarin. Leukocytes less than 4,000/µL or exceeding 10,000/µL. Platelets less than 100,000/µL. Hemoglobin less than 10 g/dL. AST (GOT) exceeding 100 IU/L or ALT (GPT) exceeding 100 IU/L. Patients with severe neural disorder in their legs. Patients with gait disturbance for reasons other than CLI (such as sciatic neuralgia, or vasculitis), making exercise tolerance evaluation on a treadmill with stress ECG difficult. Pregnant or nursing patients, those who may be pregnant, or those who plan on becoming pregnant before the end of the study period. Any other reason that the Clinical Supervisors or Clinical Researchers may have for considering a case unsuitable for the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Takayuki Asahara, M.D.
Organizational Affiliation
Institute of Biomedical Research and Innovation, Kobe, Hyogo, Japan
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kobe City General Hospital
City
Kobe
State/Province
Hyogo
ZIP/Postal Code
650-0046
Country
Japan
Facility Name
Institute of Biomedical Research and Innovation
City
Kobe
State/Province
Hyogo
ZIP/Postal Code
650-0047
Country
Japan

12. IPD Sharing Statement

Citations:
PubMed Identifier
15308462
Citation
Asahara T, Kawamoto A. Endothelial progenitor cells for postnatal vasculogenesis. Am J Physiol Cell Physiol. 2004 Sep;287(3):C572-9. doi: 10.1152/ajpcell.00330.2003.
Results Reference
background
PubMed Identifier
12551872
Citation
Kawamoto A, Tkebuchava T, Yamaguchi J, Nishimura H, Yoon YS, Milliken C, Uchida S, Masuo O, Iwaguro H, Ma H, Hanley A, Silver M, Kearney M, Losordo DW, Isner JM, Asahara T. Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation. 2003 Jan 28;107(3):461-8. doi: 10.1161/01.cir.0000046450.89986.50.
Results Reference
background
PubMed Identifier
11156872
Citation
Kawamoto A, Gwon HC, Iwaguro H, Yamaguchi JI, Uchida S, Masuda H, Silver M, Ma H, Kearney M, Isner JM, Asahara T. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation. 2001 Feb 6;103(5):634-7. doi: 10.1161/01.cir.103.5.634.
Results Reference
background
PubMed Identifier
9020076
Citation
Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997 Feb 14;275(5302):964-7. doi: 10.1126/science.275.5302.964.
Results Reference
background
PubMed Identifier
10202935
Citation
Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M, Isner JM, Asahara T. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999 Apr;5(4):434-8. doi: 10.1038/7434.
Results Reference
background
PubMed Identifier
10725398
Citation
Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T, Isner JM, Asahara T. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3422-7. doi: 10.1073/pnas.97.7.3422.
Results Reference
background
PubMed Identifier
22877866
Citation
Kinoshita M, Fujita Y, Katayama M, Baba R, Shibakawa M, Yoshikawa K, Katakami N, Furukawa Y, Tsukie T, Nagano T, Kurimoto Y, Yamasaki K, Handa N, Okada Y, Kuronaka K, Nagata Y, Matsubara Y, Fukushima M, Asahara T, Kawamoto A. Long-term clinical outcome after intramuscular transplantation of granulocyte colony stimulating factor-mobilized CD34 positive cells in patients with critical limb ischemia. Atherosclerosis. 2012 Oct;224(2):440-5. doi: 10.1016/j.atherosclerosis.2012.07.031. Epub 2012 Jul 27.
Results Reference
derived
PubMed Identifier
19711453
Citation
Kawamoto A, Katayama M, Handa N, Kinoshita M, Takano H, Horii M, Sadamoto K, Yokoyama A, Yamanaka T, Onodera R, Kuroda A, Baba R, Kaneko Y, Tsukie T, Kurimoto Y, Okada Y, Kihara Y, Morioka S, Fukushima M, Asahara T. Intramuscular transplantation of G-CSF-mobilized CD34(+) cells in patients with critical limb ischemia: a phase I/IIa, multicenter, single-blinded, dose-escalation clinical trial. Stem Cells. 2009 Nov;27(11):2857-64. doi: 10.1002/stem.207.
Results Reference
derived
Links:
URL
http://www.ibri-kobe.org/english/index.html
Description
Foundation for Biomedical Research and Innovation, Kobe, Japan

Learn more about this trial

Stem Cell Study for Patients With Leg Ulcer/Gangrene

We'll reach out to this number within 24 hrs